IMJUDO J Code: J9347

Drug & Product Overview

HCPCS Descriptor Injection, tremelimumab-actl, 1 mg

HCPCS Added Date July 1, 2023

Manufacturer Astrazeneca

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About IMJUDO

Imjudo is a medication aligned to the HCPCS J Code: J9347 for billing, pricing, and reimbursement purposes in the United States. Classified under Misc., it is administered via the intravenous route and manufactured by Astrazeneca.

According to CMS Drug Use Information: Tremelimumab is used to treat certain cancers (such as liver, lung). It works by helping your immune system fight the cancer. This medication belongs to a class of drugs known as monoclonal antibodies.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
00310-4505-25	Imjudo	AstraZeneca Pharmaceuticals LP	25	25 MG / 1.25 ML
00310-4535-30	Imjudo	AstraZeneca Pharmaceuticals LP	300	300 MG / 15 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

IMJUDO Pricing & Reimbursement

J9347 Private Payer Reimbursement

$147.86 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

IMJUDO Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 19.22%

Avg. Days to File 14.1days

Avg. Days to Pay 32.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9347 claims analytics on FocalPoint →

IMJUDO CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Imjudo (J9347) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

IMJUDO Medically Unlikely Edits (MUE)

The most billing units of J9347 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

300 units / day

= 300 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

IMJUDO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Metastatic non-small cell lung cancer Unresectable hepatocellular carcinoma

Drug Class

CTLA-4-directed Antibody Interactions [MoA]CTLA-4-directed Blocking Antibody [EPC]Increased T Lymphocyte Activation [PE]

Frequently Asked Questions

Is there an available Imjudo billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for IMJUDO.

Are there any available Imjudo patient assistance programs?

IMJUDO patient assistance information can be found through Astrazeneca Pharmaceuticals, Lp. Visit Here →

Where can I find Imjudo prescribing information?

IMJUDO prescribing information can be found at the link below: Visit Here →

Where can I find Imjudo side effect information?

Information regarding IMJUDO's side effects can be found at MedlinePlus Visit Here →

Does billing IMJUDO require JZ/JW wastage modifiers?

CMS has identified IMJUDO(J9347) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.